Background
==========

Cyclosporine A (CsA, calcineurin inhibitor) considerably improves survival after heart transplantation, leading to its widespread use over the last 25 years \[[@B1],[@B2]\]. The last registry report of the International Society for Heart and Lung Transplant (ISHLT) provides overall survival rates of 80, 70, and 55% after one, five, and ten years, respectively \[[@B3]\].

This long-term survival is impaired by CsA side effects; in particular, nephrotoxicity that frequently leads to renal impairment. Retrospective studies have shown a 5 to 10% risk of chronic renal failure in patients treated with CsA after heart transplantation \[[@B2],[@B4]-[@B6]\]. After transplantation of a non-renal organ, patients have a five-year risk of chronic renal failure from 7 to 21%, depending on what kind of organ is transplanted \[[@B5]\].

To limit renal impairment, several approaches have been explored in renal, cardiac, and liver transplantation. Immunosuppressive regimens have used mycophenolate mofetil (MMF) in combination with a calcineurin inhibitor (CNI) \[[@B7]\]. These efficient strategies foster the use of reduced CNI doses after the first high-risk rejection period after transplantation. In long-term heart transplant recipients with chronic renal dysfunction, a significant improvement in renal function and metabolic profile with no increased risk of acute rejection episodes was observed \[[@B8],[@B9]\].

The use of reduced CsA doses immediately after renal transplantation has already been assessed in clinical trials \[[@B10]-[@B14]\]. Results suggest a benefit on renal function with a reduction in serum creatinine levels without a significant change in clinical endpoints (biopsy-proven rejection episodes, death). However, these trials were not sufficiently powered to prove clinical outcomes, but each of them adds a piece of the puzzle and should be available through publication in order to reduce the risk of bias when carrying out a systematic review.

Therefore, the reduction of CsA nephrotoxic effects using low doses immediately after heart transplantation, although attractive, has not been formally evaluated yet. The present study investigated the effect of an early low dose of CsA plus MMF on the change in serum creatinine level over a year in *de novo* heart transplant recipients.

Methods
=======

Study design and ethics
-----------------------

This is a prospective, multicentre, open-label, randomised, parallel-group study. It was investigator designed. The study was approved by the Ethics Committee of the Centre Léon Bérard (Lyon, France), declared to the French Agency for the Safety of Health Products (AFSSAPS), registered on ClinicalTrials.gov under number NCT00159159, and conducted in accordance with the European Guidance for Good Clinical Practice and the Declaration of Helsinki.

Randomisation and treatment
---------------------------

Within four days post-surgery, patients undergoing *de novo* heart transplantation were randomised to receive either a low dose or a standard dose of CsA, in a 1/1 ratio, as part of a triple immunosuppressant regimen, including MMF, and corticosteroids.

Patients were randomised using a centralised procedure. Randomisation was stratified by centre, age, presence of ischemia, and serum creatinine level before transplantation. Patients were followed up for 12 months. During the first three months, the low-dose group received CsA targeting a whole blood pre-dose concentration (C0) of 130 to 200 μmol/L, whereas the standard-dose group received CsA with a C0 between 200 and 300 μmol/L. Both doses reflect current practice \[[@B15]\]. Thereafter, to follow standard practice, the CsA doses of the standard-dose group were tapered to match the C0 of the low-dose group (130 μmol/L to 200 μmol/L).

The immunosuppressive treatment also included MMF (3 g daily) and corticosteroids according to local practice. MMF doses were adjusted according to individual tolerance.

All other concomitant antibacterial, antifungal, antiviral, anticholesterol, or antihypertensive drugs were administered at the discretion of physicians.

Patients
--------

Overall, 95 patients were enrolled in 10 French heart transplantation centres. Male and female heart transplant patients, aged 18 to 65, undergoing *de novo* heart transplantation were eligible. Donors' cold ischemia time was under six hours. The main recipient exclusion criteria were: unstable haemodynamic status at the time of randomisation, circulatory assistance, serum creatinine level \>250 μmol/L, multiorgan transplant, history of malignant disease within the past five years, a human immunodeficiency virus-positive blood test, a positive HB-antigen test, or a positive PCR hepatitis C test. Pregnant or breastfeeding women, patients participating in another trial, drug addicts, and psychiatric patients were also excluded. Each participant gave written informed consent.

Study objectives, primary and secondary endpoints
-------------------------------------------------

The primary objective was to compare the renal function between the two groups by assessing changes in serum creatinine levels from inclusion up to 12 months. Creatinine clearance, microalbuminuria, and proteinuria were used as secondary endpoints. Immunosuppressive efficacy endpoints included the incidence of acute rejection episodes, the assessment of cardiac function (ejection and shortening fractions), and treatment failure (defined as death or withdrawal from the study for any reason). Any time during participation, the treatment was to be discontinued in patients of the low-dose group who received less than 1.5 g MMF/day for more than 15 consecutive days.

In compliance with the intention-to-treat (ITT) analysis of the primary endpoint, patients who withdrew early were followed up until the end of the study.

Strategy tolerance was assessed by the incidence of adverse events. Vital signs (weight and clinical manifestations) and cardiovascular risk factors (blood pressure, lipid, and glucose profiles) were closely monitored at each outpatient visit.

Clinical follow-up
------------------

Following standard clinical procedures, the patients were monitored every two weeks during the first three months, then at months 4, 5, 6, 9, and 12 post-transplantation to assess the efficacy and safety of the strategy. Serum creatinine level was assessed at each visit. Creatinine clearance, proteinuria, and albuminuria were analysed at months 6 and 12. Cystatin C was assessed at inclusion, then at 1, 2, 3, 6, and 12 months.

Endomyocardial biopsies were performed according to local procedures. Biopsy-proven acute rejection episodes were graded by a local pathologist using the International Society for Heart and Lung Transplantation (ISHLT) scale. All biopsies performed over the study period were considered for analysis \[[@B16]\]. Acute rejection episodes were considered serious adverse events and the sponsor was immediately notified.

Statistical analysis
--------------------

Forty-five patients in each group (53 recruited for a drop-out of 15%) would ensure a 80% power to detect an 18% reduction in serum creatinine level of the low-dose group, at 12 months, assuming that the mean in the standard-dose group is 140 μmol/L, the common standard deviation is 43, and the two-sided two-group *t* test significance level is 0.05 \[[@B17]\].

According to the intention-to-treat (ITT) principle, analyses were performed on all 95 randomised patients.

Given biological variability and the imprecision of measurements, a mixed model of co-variance was used to take into account all available measures. The main analysis focused on a three- to twelve-month interval. It tested the effects of treatment at three months (low dose vs. standard dose) and whether the expected change lasted until the end of follow-up, when both groups started to receive the same low dose. Missing data were included as random events. The treatment effect was tested both on the intercept (treatment effect at three months) and on the slope (interaction between treatment and time of follow-up). The likelihood ratio test was used for this test comparing the models given below:

$$Model\mspace{2mu} 1:\eta_{\mathit{ij}} = \beta_{0} + \beta_{1}X1_{\mathit{ij}} + U_{i0}$$

$$Model\mspace{2mu} 2:\eta_{\mathit{ij}} = \beta_{0} + \beta_{1}X1_{\mathit{ij}} + \beta_{2}X2 + \beta_{3}X1_{\mathit{ij}}X2 + U_{i0} + U_{i1}X1_{\mathit{ij}}X2_{i}$$

Where η~ij~ is the predicted creatinine value (log10-transformed) for patient i and measurement j, X1~ij~ is the time elapsed after transplantation (in days), X2~i~ is the patient group, X1~ij~ X2~i~ is the interaction between the patient group and the time interval, U~i0~ is the random intercept for patient i, and U~i1~ is the random slope for patient i.

A box plot distribution was used to describe changes in creatinine level over time by treatment group.

A post hoc analysis was conducted on the primary endpoint dichotomised according to a clinically meaningful threshold (\>120 μmol/L) in order to check that the low dose was able to decrease the proportion of patient over this threshold after three months and/or up to twelve months.

The threshold of 120 μmol/L was considered as clinically critical on the basis of literature data and clinical observations \[[@B18],[@B19]\]. Our hypothesis was that the low dose could have a greater impact among the patients with the highest creatinine values. A hierarchical logistic regression model using a penalised quasi-likelihood method (glmmPQL) was used to test this hypothesis. The formula was similar to Model 2, but here, η~ij~ was the probability of having a creatinine level over the threshold (logit transformation).

The statistical analysis used R and SAS™ softwares.

Results
=======

The flow diagram of the study is presented in Figure [1](#F1){ref-type="fig"}. Between March 2004 and December 2005, 95 eligible patients were included and randomised: 47 patients in the low-dose group and 48 in the standard-dose group of CsA treatment. The last follow-up visits took place in December 2006. All 95 patients underwent heart transplantation, received the assigned treatment, and were included in the ITT analysis.

![Study flow diagram](1745-6215-13-231-1){#F1}

The study was completed by 33 patients in the low-dose group and 38 patients in the standard-dose group. In the two groups, treatment discontinuation was the main reason for withdrawal; however, the number of discontinuations was lower in the standard-dose group than in the low-dose group (10.4% vs. 27.7%, *P* = 0.039).

The baseline characteristics of participants at inclusion are summarised in Table [1](#T1){ref-type="table"}. Except for a higher proportion of females in the standard-dose group than in the low-dose group, all other variables were comparable in the two groups of patients.

###### 

Baseline characteristics of the study population

  **Characteristics**                                **Low-dose group**   **Standard-dose group**
  ------------------------------------------------- -------------------- -------------------------
  Age, mean (SD), y                                     49.3 (10.2)             48.2 (11.5)
  Sex                                                                    
   Male n (%)                                            36 (76.6%)             29 (60.4%)
   Female n (%)                                          11 (23.4%)             19 (39.6%)
  Weight, mean (SD), kg                                   72 (14)                 69 (16)
  Serum creatinine, mean (SD), μmol/L                   1247 (44.2)            126.5 (47.8)
  Delay to cyclosporine A (CsA) use, mean (SD), d         1.9 (1)                 1.9 (1)
  Pre-transplantation on heart disease:                                  
   Idiopathic, n (%)                                     18 (38.3%)             18 (37.5%)
   Coronaropathy, n (%)                                   16 (34%)              18 (37.5%)
   Congenital cardiopathy, n (%)                          2 (4.3%)               3 (63.3%)
   Valvular pathology, n (%)                              1 (2.1%)               3 (63.3%)
   Other, n (%)                                          10 (21.3%)              6 (12.5%)
  Cytomegalovirus serology                                                            
  Donor^+^/Recipient^-^, n (%)                                                        

C0 levels were generally met in the two groups with values in the upper end of the target range in the low-dose group. For the first three months, C0 levels were significantly higher in the standard-dose group than in the low-dose group (*P* \<0.001) but the two group distributions overlapped with 16% of the values under the threshold of 200 μmol/L in the standard-dose group and 17% of the values over the threshold of 130 μmol/L in the low-dose group. As expected, from three months after heart transplantation until the end of the study, C0 levels were similar in the two groups. All patients received induction treatment with polyclonal antibodies except for one patient in the standard-dose group.

Efficacy assessment
-------------------

At 12 month post-transplantation, serum creatinine levels were available for 91 patients. At intermediate visits, data were available for 89 to 91 patients. Some data were missing for one to two patients at different study time-points. Observed creatinine values displayed strong individual variability. The results showed no significant difference in renal function changes between the two groups (*P* = 0.162) despite a trend towards a lower impairment of renal function in the low-dose group between three and twelve months (Table [2](#T2){ref-type="table"}).

###### 

Primary and secondary renal function outcomes

                                                                    **Delay after heart transplantation**  **Low-dose group**   **Standard-dose group**   ***P*value†**                   
  ------------------------------------------------------------------------------------------------------- -------------------- ------------------------- --------------- ---------------- -------
                                                                                         Creatinine level                                                                                     
                                                                                              At baseline          47                  125(44)\*               48            127(48)       0.59
                                             Low versus standard cyclosporine A (CsA) regimen maintained:                                                                                  \-\--
                                                                                             At 0.5 month          47                   101(30)                47            116(62)       \-\--
                                                                                               At 1 month          47                   105(40)                46            121(73)       \-\--
                                                                                             At 1.5 month          47                   106(44)                45            116(48)       \-\--
                                                                                              At 2 months          47                   104(42)                45            113(50)       \-\--
                                                                                            At 2.5 months          45                   101(40)                44            113(49)       \-\--
                                                                                              At 3 months          46                   103(30)                45            119(57)       0.062
                                                                                        Same CsA regimen:                                                                                 
                                                                                              At 4 months          45                   105(29)                44            123(46)       \-\--
                                                                                              At 5 months          47                   110(29)                44            126(47)       \-\--
                                                                                              At 6 months          47                   107(28)                45            128(72)       0.065
                                                                                              At 9 months          47                   116(33)                45            131(49)       \-\--
                                                                                             At 12 months          46                   121(36)                45            132(49)        0.2
    †*P* value of the global test (likelihood ratio test) for treatment effect after three months = 0.162                                                                                 
                                                                                     Creatinine clearance                                                                                 
                                                                                                 6 months          27               76.7(31.4)\*\*             33         66.1(29.4)\*\*    NS
                                                                                                12 months          23               72.7(31.7)\*\*             23         66.9(26.1)\*\*    NS
                                                                                               Cystatin C                                                                                 
                                                                                                 3 months          36                1.21(0.44)††              33           1.5(0.7)††     0.04
                                                                                                 6 months          35                1.25(0.34)††              31           1.5(0.9)††      NS
                                                                                                12 months          35                1.29(0.40)††              30           1.4(0.7)††      NS

\*Creatinine values are expressed as means (SD) in μmol/L, \*\*creatinine clearance values are expressed as means (SD) in mL/min, ††cystatin values are expressed as means (SD) in mg/L.

Figure [2](#F2){ref-type="fig"} presents a box plot distribution of observed serum creatinine values. After one month of treatment and during all of follow-up, the upper quartile was systematically lower in the low-dose group than in the standard-dose group. At three months, the post hoc analysis in patients with baseline creatinine \>120 μmol/L showed a significantly lower number of patients above the clinically defined threshold in the low-dose group than in the standard-dose group (13% vs. 33%, *P* = 0.026) but the difference did not remain statistically significant thereafter and the treatment effect, as estimated by the hierarchical logical regression model on all available measures, was not statistically significant.

![**Box plot distributions of observed serum creatinine values in standard-dose and low-dose patients by visit (months).** Reference horizontal line at 120 μmol/L.](1745-6215-13-231-2){#F2}

Other renal function parameters were favourable to the low-dose regimen despite the absence of significant differences (except for Cystatin C at three months) (Table [2](#T2){ref-type="table"}).

Safety assessment
-----------------

### Death

Four deaths were reported (Figure [1](#F1){ref-type="fig"}): one in the low-dose group (septic shock) and three in the standard-dose group (one herpetic infection with hepatocellular dysfunction, one pseudomonas septicaemia associated with cytomegalovirus infection, and one case of non-compliance with the immunosuppressive treatment). At 12 months, the survival was comparable between the low-dose (97.9%) and the standard-dose group (95.8%). No graft loss was reported during the study period.

### Immunosuppressive efficacy

The incidence of acute rejection episodes, whatever their grade, was similar between the two groups (n = 41, 87.3%, in the low-dose group vs. n = 43, 91.5% in the standard-dose group). Treatment for rejection episodes graded 1B or higher concerned 20 patients (42.6%) in the low-dose group and 17 patients (36.2%) in the standard-dose group. The incidence of rejection episodes graded 3A or higher, usually taken as serious by clinicians, was 17% in the low-dose group and 14.6% in the standard-dose group (Table [3](#T3){ref-type="table"}). The relative risk of severe acute rejection was 1.14 (95% confidence interval (0.45 to 2.90)).

###### 

Histological grade of graft rejections

   **Rejection grade**   **Low-dose group**   **Standard-dose group**   ***P*value**        
  --------------------- -------------------- ------------------------- -------------- ----- ----
           1A                 38 (81%)                  148               39 (83%)     178   NS
           1B                20 (42.6%)                 34               17 (36.2%)    45    NS
            2                 3 (6.4%)                   6                8 (17%)       8    NS
           3A                7 (14.9%)                   9               7 (17.9%)      8    NS
           3B                 1 (2.1%)                   1                   0          0    NS

### Study withdrawals

Treatment was discontinued in 10 patients of the low-dose group who received a MMF dose below 1.5 g/day for more than 15 consecutive days. Tacrolimus was used instead of cyclosporine in three patients of the low-dose group and five patients of the standard-dose group. Other reasons for withdrawal were one renal failure and one deviation from the protocol in the standard-dose group.

### Other safety assessments

Excluding rejection episodes, at least one adverse event was reported in 91.6% of the participants: 93.6% in the low-dose group vs. 89.6% in the standard-dose group. Serious adverse events were reported in 69.5% of the participants: 72.3% in the low-dose group vs. 66.7% in the standard-dose group.

During the study period, more dialysis episodes were observed in the standard-dose group than in the low-dose group, but the difference was not statistically significant. Six patients had at least one dialysis episode: one (2.1%) in the low-dose group vs. five (10.4%) in the standard-dose group (*P* = 0.097).

The overall incidence of infections was similar between both groups. The incidence of cytomegalovirus infection (PCR-positive, and/or infection) was 30% in the low-dose group and 25% in the standard-dose group.

At 12 months, the mean systolic and diastolic blood pressures were not significantly different: 136 ± 16.1 vs. 134 ± 13.5 and 85 ± 14 vs. 85 ± 11 in the low-dose and standard dose groups, respectively. All patients received statins and mean total cholesterol and triglyceride levels remained within normal ranges and did not differ between the two groups (5.09 ± 1.12 vs. 5.07 ± 1.01 mmol/L for cholesterol and 1.66 ± 0.86 vs. 1.58 ± 0.84 mmol/L for triglycerides in the low-dose and the standard-dose groups, respectively).

Discussion
==========

Over 12 months, we observed less renal function impairment in heart transplant patients receiving a low dose of CsA than in those receiving a standard dose. However, differences in creatinine levels between three and twelve months were not statistically significant.

Several reasons may explain these results. First, the observed difference at 12 months (12 μmol/L) was lower than expected (24 μmol/L for an 18% reduction). Second, during the period under different dose regimens, the two group distributions of blood CsA values overlapped. During the first three months in the low-dose group, the C0 level remained at the upper end of the target range reflecting difficulties for physicians to significantly reduce CsA doses. This difficulty has already been reported \[[@B9]\]. Third, the primary endpoint was assessed at 12 months; that is, after nine months of identical dose regimens but the observed difference decreased after three months under the same regimen. Therefore, the low-dose strategy was not long enough to have a strong impact on the results at 12 months. Fourth, the important heterogeneity of individual responses over time has probably affected the power of the analysis. Finally, the lower frequency of high creatinine values (upper quartile) between three and twelve months in the low-dose group suggests different response profiles possibly linked to the severity of renal impairment. Even though less patients with severe renal impairment (creatinine \>120 μmol/L) were seen at three months in the low-dose group, the post hoc analysis was not able to show a statistically significant effect, possibly because of a lack of power.

Furthermore, a lower number of dialysis episodes were reported in the low-dose group than in the standard-dose group, but this was not statistically significant. A meta-analysis by subgroup is being conducted to confirm whether or not patients with severe renal impairment benefit from low-dose cyclosporine after heart transplant. Other renal function indicators (creatinine clearance, cystatin C) progressed at the same rate as our primary endpoint, which is clinically consistent.

Overall, cardiac function remained stable and comparable between the two treatment groups and, consistently with other heart-transplant studies, serious adverse events were frequent but not different between the two groups.

An important number of patients under low-dose CsA withdrew from the study because of intolerance to MMF. In the study protocol, MMF \<1.5 g/day for more than 15 consecutive days was a reason for withdrawal only in the low-dose group. Also, at the time of the trial, the choice was made to maintain patients at 3 g MMF/day without controlling blood levels. However, in patients with renal insufficiency recommendations were changed to a reduction of MMF dosage to 2 g/day and the use of blood-level monitoring \[[@B20]\].

The present trial showed that there was no difference between the two groups regarding the incidence of severe acute rejection episodes. However, due to the small size of the study, an increased risk of severe acute rejection episodes in the low-dose group cannot be excluded. The use of post hoc combined criteria that include dialysis plus death (two cases in the low-dose group vs. eight cases in the standard-dose group, *P* = 0.049) may lead to benefits when reducing CsA soon after heart transplantation. These results could be relevant to 25% of patients in the first year after heart transplant, who take CsA as a first-line treatment \[[@B21]\].

Several limitations of our study have to be acknowledged. These include the small number of new heart transplantations in France, possible biases related to the open-label design of the study, the choice of an endpoint devoid of direct clinical relevance, and the insufficient power to address all dimensions of the risk/benefit ratio of the newly proposed strategy. Nevertheless, this study is the first French multicentre trial in heart transplantation that addressed this daily specialist concern. Obviously, our results cannot be viewed as a definitive answer to the issue of the risk/benefit ratio of the CsA reduction strategy, but they may foster future research in the same direction and orient future studies towards a success/failure approach. They explore whether patients fitting particular individual profiles are more likely to benefit from a low-dose CsA strategy.

Conclusions
===========

In patients with *de novo* cardiac transplantation, early Cyclosporine A dose reduction was not associated with renal benefit at 12 months. However, the strategy may benefit patients with high creatinine levels before transplantation.
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